ArticleBMC cardiovascular disorders2015
Troponin in diabetic patients with and without chronic coronary artery disease.
Article in BMC cardiovascular disorders, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it, 43 citations in OpenAlex.
- Prognostic performance of troponin in COVID-19: A diagnostic meta-analysis and meta-regression.International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases · 2021Pooled it
- Cardioprotective Effect of Nigella sativa in Pediatric Patients with Type 1 Diabetes Mellitus: A Randomized Controlled Study.Paediatric drugs · 2025Trial
- Role of Circulating Biomarkers in Diabetic Cardiomyopathy.Biomedicines · 2024Review
- Article
- Associations of elevated cardiac biomarkers with hyperuricemia and mortality in US adults without prevalent cardiovascular disease.Frontiers in endocrinology · 2024Article
- High-Sensitivity Troponin I and Cardiovascular Events in Stable Coronary Artery Disease: Insights from a Longitudinal Outpatient Study.International journal of molecular sciences · 2023Article
- Cardioprotective and Antifibrotic Effects of Low-Dose Renin-Angiotensin-Aldosterone System Inhibitors in Type 1 Diabetic Rat Model.International journal of molecular sciences · 2023Article
- Lower odds of COVID-19-related mortality in hospitalised patients with type II diabetes mellitus: A single-centre study.PloS one · 2023Observational
- Immune-inflammatory biomarkers and the risk of cardiac injury in COVID-19 patients with diabetes: a retrospective cohort study.Cardiovascular diabetology · 2022Article
- Cardiovascular biomarkers in pregnancy with diabetes and associations to glucose control.Acta diabetologica · 2022Article
- Nitrotyrosine, Nitrated Lipoproteins, and Cardiovascular Dysfunction in Patients with Type 2 Diabetes: What Do We Know and What Remains to Be Explained?Antioxidants (Basel, Switzerland) · 2022Review
- SGLT2 inhibitor dapagliflozin prevents atherosclerotic and cardiac complications in experimental type 1 diabetes.PloS one · 2022Article
- Clinical characteristics and prognostic implications of diabetes and myocardial injury in patients admitted to the emergency room.BMC cardiovascular disorders · 2021Article
- Role of novel biomarkers in diabetic cardiomyopathy.World journal of diabetes · 2021Review
- Protein oxidation - Formation mechanisms, detection and relevance as biomarkers in human diseases.Redox biology · 2021Review
- The Role of Antioxidants Supplementation in Clinical Practice: Focus on Cardiovascular Risk Factors.Antioxidants (Basel, Switzerland) · 2021Review
- Vascular Effects of Avocado Seed Glycosides during Diabetes-induced Endothelial Damage.Cardiovascular & hematological disorders drug targets · 2020Article
- Relationship between hemoglobin A1c and serum troponin in patients with diabetes and cardiovascular events.Journal of diabetes and metabolic disorders · 2019Review
- Assessing Cardiovascular Risk and Testing in Type 2 Diabetes.Current cardiology reports · 2017Review
- Association between troponin I level and cardiovascular risk factors in asymptomatic hemodialysis patients.Journal of research in pharmacy practiceArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCardiac-specific troponin detected with the new high-sensitivity assays can be chronically elevated in response to cardiovascular comorbidities and confer important prognostic information, in the absence of unstable coronary syndromes. Both diabetes mellitus and coronary artery disease are known predictors of troponin elevation. It is not known whether diabetic patients with coronary artery disease have different levels of troponin compared with diabetic patients with normal coronary arteries. To investigate this question, we determined the concentrations of a level 1 troponin assay in two groups of diabetic patients: those with multivessel coronary artery disease and those with angiographically normal coronary arteries.
methodsWe studied 95 diabetic patients and compared troponin in serum samples from 50 patients with coronary artery disease (mean age = 63.7, 58 % male) with 45 controls with angiographically normal coronary arteries. Brain natriuretic peptide and the oxidative stress biomarkers myeloperoxidase, nitrotyrosine and oxidized LDL were also determined.
resultsDiabetic patients with coronary artery disease had higher levels of troponin than did controls (median values, 12.0 pg/mL (95 % CI:10-16) vs 7.0 pg/mL (95 % CI: 5.9-8.5), respectively; p = 0.0001). The area under the ROC curve for the diagnosis of CAD was 0.712 with a sensitivity of 70 % and a specificity of 66 %. Plasma BNP levels and oxidative stress variables (myeloperoxidase, nitrotyrosine, and oxidized LDL) were not different between the two groups. In a multivariate analysis, gender (p = 0.04), serum glucose (0.03) and Troponin I (p = 0.01) had independent statistical significance.
conclusionTroponin elevation is related to the presence of chronic coronary artery disease in diabetic patients with multiple associated cardiovascular risk factors. Troponin may serve as a biomarker in this high-risk population.
trial registrationhttp://www.controlled-trials.com REGISTRATION NUMBER: ISRCTN26970041.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.